INmune Bio Inc.
INMB
$2.17
$0.094.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 76.46% | -2.72% | 18.67% | 73.54% | -151.13% |
| Total Depreciation and Amortization | 26.92% | -7.14% | 100.00% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.41% | -57.60% | 40.63% | -86.93% | 769.36% |
| Change in Net Operating Assets | -709.16% | 151.90% | 22.25% | -40.21% | -215.02% |
| Cash from Operations | 6.70% | -15.59% | 45.87% | 26.25% | -8.07% |
| Capital Expenditure | -- | -- | 25.91% | 72.66% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 25.91% | 72.66% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | 322.28% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -100.00% | 322.28% |
| Foreign Exchange rate Adjustments | -1,010.00% | -72.97% | 562.50% | 94.77% | -337.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 13.14% | -13.74% | 47.11% | -140.18% | 985.62% |